Overall rank by patents
#10,340
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Hangzhou Biotest Biotech Co., Ltd.
USPTO PatentsView assignee record - 30 granted patents across 3 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE).
30
Total patents granted
3
CPC technology areas
5.6
Avg claims per patent
-
5-year filing velocity
The verdict
Hangzhou holds 30 US patents across 3 technology areas, rank #10,340 of 50,000 tracked assignees.
- #10,340
- of 50,000 US assignees by volume
- Top 60%
- by Innovation Score (32.2/100)
- 5.6
- avg claims per patent
Portfolio overview
HANGZHOU BIOTEST BIOTECH CO., LTD. has been granted 30 US utility patents between 2020 and 2025, placing HANGZHOU BIOTEST BIOTECH CO., LTD. at rank #10,340 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.6 claims per patent with primary concentration in B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE). As a Foreign Corporation, HANGZHOU BIOTEST BIOTECH CO., LTD. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 32.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 30 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. HANGZHOU BIOTEST BIOTECH CO., LTD.'s 5.6 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark HANGZHOU BIOTEST BIOTECH CO., LTD. against peers pursuing similar technology classes.
How does HANGZHOU compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Hangzhou Biotest… ◀ 30
HANGZHOU BIOTEST BIOTECH CO., LTD.
30 patents
What this shows HANGZHOU holds 30 patents, placing it at rank #10,340 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
HANGZHOU's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 60% higher than 40% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2020–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 5 | 16.7% |
| 2021 | 3 | 10.0% |
| 2022 | 6 | 20.0% |
| 2023 | 4 | 13.3% |
| 2024 | 3 | 10.0% |
| 2025 | 9 | 30.0% |
Which technologies does HANGZHOU BIOTEST BIOTECH CO., LTD. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Frequently Asked Questions
How many patents does HANGZHOU BIOTEST BIOTECH CO., LTD. hold?
HANGZHOU BIOTEST BIOTECH CO., LTD. holds 30 US granted patents filed between 2020 and 2025, spanning 3 technology areas.
What is HANGZHOU BIOTEST BIOTECH CO., LTD.'s Innovation Score?
HANGZHOU BIOTEST BIOTECH CO., LTD. has an Innovation Score of 32.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does HANGZHOU BIOTEST BIOTECH CO., LTD. focus on?
HANGZHOU BIOTEST BIOTECH CO., LTD.'s top technology area is B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE) with 8 patents. The company has filed patents in 3 CPC subclasses total.
Is HANGZHOU BIOTEST BIOTECH CO., LTD.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for HANGZHOU BIOTEST BIOTECH CO., LTD..
What does claim depth mean for HANGZHOU BIOTEST BIOTECH CO., LTD.'s patents?
HANGZHOU BIOTEST BIOTECH CO., LTD.'s patents average 5.6 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the HANGZHOU BIOTEST BIOTECH CO., LTD. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Hangzhou's 30 grants land it in the top 60% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Hangzhou ranks #10,340 of 50,000. Top 50 holders
- Most of this portfolio concentrates in B01L - see who else leads that technology area. B01L leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
B01L technology
HANGZHOU BIOTEST BIOTECH CO., LTD.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where HANGZHOU BIOTEST BIOTECH CO., LTD. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
